Virscio Inc
Hamden, CT · Biotech · Private
Nonhuman primate model of Alzheimer's disease induced by intrathecal amyloid-beta oligomer administration for preclinical drug testing
- Grants
- $4.6M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Amyloid Beta Oligomer Induction of Alzheimer's Disease in Nonhuman Primates | $208,412 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Amyloid Beta Oligomer Induction of Alzheimer's Disease in Nonhuman Primates | $257,430 | |
| Federal grant | Department of Health and Human Services · Phase I · Amyloid Beta Oligomer Induction of Alzheimer's Disease in Nonhuman Primates | $49,018 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid Beta Oligomer Induction of Alzheimer Disease in Nonhuman Primates | $1,119,343 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid Beta Oligomer Induction of Alzheimer Disease in Nonhuman Primates | $1,890,136 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid Beta Oligomer Induction of Alzheimer Disease in Nonhuman Primates | $770,793 | |
| Federal grant | Department of Health and Human Services · Phase I · Primate epigenetic and senescence biomarkers to advance aging science and anti-aging strategies. | $291,913 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1514 | Juvenescence | — | $115M |
| 1515 | REPLICEL LIFE SCIENCES INC. | — | $5.8M |
| 1516 | Ideaya Biosciences, Inc. | — | $111M |
| 1517 | Virscio Inc | — | — |
| 1518 | Moonwalk Biosciences | — | $110M |
| 1519 | DEGROME THERAPEUTICS, INC. | — | — |
| 1520 | Bell Biosystems, Inc. | — | $2.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.